Drugs / IBEROGAST
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02719496 | Apr 2016 → Apr 2018 | digestive system disorder | Nantes University Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT02660970 Comparator | Jan 2016 → Sep 2020 | functional gastric disease | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iberogast | “The majority of children suffering from functional nausea in Europe are treated with Iberogast®. a herbal mixture, whose effect was demonstrated in several studies.” NCT02660970 ↗ |
| Known as | STW-5 | “Comparison of the Therapeutic Effect of Acupressure Therapy and Iberogast ® (STW-5) in Children With Functional Nausea” NCT02660970 ↗1“The STW5 (Iberogast, Steigerwald, Germany) is a herbal agent composed of nine plant extracts” NCT02719496 ↗ |